Oriana Tabarrini

List of Publications by Year
in descending order

108	3,190	136885	206029
papers	citations	32 h-index	48 g-index

113	113	113	3472
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity. Journal of Medicinal Chemistry, 2015, 58, 9601-9614.	2.9	175
2	A 1,8-Naphthyridone Derivative Targets the HIV-1 Tat-Mediated Transcription and Potently Inhibits the HIV-1 Replication. Journal of Medicinal Chemistry, 2010, 53, 641-648.	2.9	122
3	6-Aminoquinolones as New Potential Anti-HIV Agents. Journal of Medicinal Chemistry, 2000, 43, 3799-3802.	2.9	105
4	Evolution from a Natural Flavones Nucleus to Obtain 2-(4-Propoxyphenyl)quinoline Derivatives As Potent Inhibitors of the S. aureus NorA Efflux Pump. Journal of Medicinal Chemistry, 2011, 54, 5722-5736.	2.9	102
5	Pyrazolo[4,3-c][1,2]benzothiazines 5,5-Dioxide: A Promising New Class of Staphylococcus aureus NorA Efflux Pump Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 3568-3572.	2.9	82
6	A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Proteinâ€“Basic Protein 1 (PA-PB1) Subunits. Journal of Medicinal Chemistry, 2015, 58, 3830-3842.	2.9	81
7	Studies on 6-Aminoquinolones:Â Synthesis and Antibacterial Evaluation of 6-Amino-8-methylquinolones1. Journal of Medicinal Chemistry, 1996, 39, 436-445.	2.9	73
8	Synthesis and Anti-BVDV Activity of Acridones As New Potential Antiviral Agents1. Journal of Medicinal Chemistry, 2006, 49, 2621-2627.	2.9	71
9	Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 1598-1604.	2.9	59
10	Structureâ^'Activity Relationship Study on Anti-HIV 6-Desfluoroquinolones. Journal of Medicinal Chemistry, 2008, 51, 5454-5458.	2.9	56
11	Potent 6-Desfluoro-8-methylquinolones as New Lead Compounds in Antibacterial Chemotherapy1. Journal of Medicinal Chemistry, 1996, 39, 4952-4957.	2.9	54
12	Inhibition of Subgenomic Hepatitis C Virus RNA Replication by Acridone Derivatives: Identification of an NS3 Helicase Inhibitor. Journal of Medicinal Chemistry, 2009, 52, 3354-3365.	2.9	54
13	6-Aminoquinolones: A New Class of Quinolone Antibacterials?. Journal of Medicinal Chemistry, 1995, 38, 973-982.	2.9	51
14	Structural Investigation of Cycloheptathiophene-3-carboxamide Derivatives Targeting Influenza Virus Polymerase Assembly. Journal of Medicinal Chemistry, 2013, 56, 10118-10131.	2.9	51
15	Re-evolution of the 2-Phenylquinolines: Ligand-Based Design, Synthesis, and Biological Evaluation of a Potent New Class of Staphylococcus aureus NorA Efflux Pump Inhibitors to Combat Antimicrobial Resistance. Journal of Medicinal Chemistry, 2013, 56, 4975-4989.	2.9	51
16	Halogen Bonding in Nucleic Acid Complexes. Journal of Medicinal Chemistry, 2017, 60, 8681-8690.	2.9	51
17	Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation. Journal of Antimicrobial Chemotherapy, 2005, 56, 847-855.	1.3	50
18	Highly Potent 1,4-Benzothiazine Derivatives as KATP-Channel Openers. Journal of Medicinal Chemistry, 2003, 46, 3670-3679.	2.9	48

#	Article	IF	Citations
19	NCp7: targeting a multitasking protein for next-generation anti-HIV drug development part 1: covalent inhibitors. Drug Discovery Today, 2018, 23, 260-271.	3.2	46
20	2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction. Journal of Medicinal Chemistry, 2018, 61, 7827-7848.	2.9	46
21	Structure Modifications of 6-Aminoquinolones with Potent Anti-HIV Activity1. Journal of Medicinal Chemistry, 2004, 47, 5567-5578.	2.9	45
22	Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors. Antimicrobial Agents and Chemotherapy, 2008, 52, 3433-3437.	1.4	43
23	The Versatile Nature of the 6-Aminoquinolone Scaffold: Identification of Submicromolar Hepatitis C Virus NS5B Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 1952-1963.	2.9	43
24	Polymerase Acidic Proteinâ€“Basic Protein 1 (PAâ€“PB1) Proteinâ€“Protein Interaction as a Target for Next-Generation Anti-influenza Therapeutics. Journal of Medicinal Chemistry, 2016, 59, 7699-7718.	2.9	43
25	Structure-Based Discovery of Pyrazolobenzothiazine Derivatives As Inhibitors of Hepatitis C Virus Replication. Journal of Medicinal Chemistry, 2013, 56, 2270-2282.	2.9	40
26	Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity. European Journal of Medicinal Chemistry, 2017, 138, 128-139.	2.6	38
27	Mode of action of the 2-phenylquinoline efflux inhibitor PQQ4R againstEscherichia coli. PeerJ, 2017, 5, e3168.	0.9	38
28	New Pyrazolobenzothiazine Derivatives as Hepatitis C Virus NS5B Polymerase Palm Site I Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 3247-3262.	2.9	35
29	Design and Synthesis of Modified Quinolones as Antitumoral Acridones. Journal of Medicinal Chemistry, 1999, 42, 2136-2144.	2.9	34
30	(1,4-Benzothiazinyloxy)alkylpiperazine derivatives as potential antihypertensive agents. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 465-468.	1.0	34
31	Studies on anti-HIV quinolones: New insights on the C-6 position. Bioorganic and Medicinal Chemistry, 2009, 17, 667-674.	1.4	32
32	Computerâ€Aided Design, Synthesis and Validation of 2â€Phenylquinazolinone Fragments as CDK9 Inhibitors with Antiâ€HIVâ€1 Tatâ€Mediated Transcription Activity. ChemMedChem, 2013, 8, 1941-1953.	1.6	32
33	Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 that Block Human Cytomegalovirus Replication. Cell Chemical Biology, 2016, 23, 340-351.	2.5	32
34	Efficient and regioselective one-step synthesis of 7-aryl-5-methyl- and 5-aryl-7-methyl-2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivatives. Organic and Biomolecular Chemistry, 2017, 15, 7944-7955.	1.5	31
35	Blocking HIV-1 Replication by Targeting the Tat-Hijacked Transcriptional Machinery. Current Pharmaceutical Design, 2013, 19, 1860-1879.	0.9	31
36	Structural Investigation of the Naphthyridone Scaffold: Identification of a 1,6â€Naphthyridone Derivative with Potent and Selective Antiâ€HIV Activity. ChemMedChem, 2011, 6, 1249-1257.	1.6	30

#	Article	IF	Citations
37	Novel 1,4-Benzothiazine Derivatives as Large Conductance Ca2+-Activated Potassium Channel Openers. Journal of Medicinal Chemistry, 2008, 51, 5085-5092.	2.9	29
38	The 6-Aminoquinolone WC5 Inhibits Human Cytomegalovirus Replication at an Early Stage by Interfering with the Transactivating Activity of Viral Immediate-Early 2 Protein. Antimicrobial Agents and Chemotherapy, 2010, 54, 1930-1940.	1.4	29
39	Reducing Mutant Huntingtin Protein Expression in Living Cells by a Newly Identified RNA CAG Binder. ACS Chemical Neuroscience, 2018, 9, 1399-1408.	1.7	29
40	6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors. Future Medicinal Chemistry, 2010, 2, 1161-1180.	1.1	28
41	Searching for Novel Inhibitors of the S.â€…aureus NorA Efflux Pump: Synthesis and Biological Evaluation of the 3â€Phenylâ€1,4â€benzothiazine Analogues. ChemMedChem, 2017, 12, 1293-1302.	1.6	28
42	Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. European Journal of Medicinal Chemistry, 2017, 140, 321-330.	2.6	28
43	Pyridobenzothiazolones Exert Potent Anti-Dengue Activity by Hampering Multiple Functions of NS5 Polymerase. ACS Medicinal Chemistry Letters, 2020, 11, 773-782.	1.3	28
44	Synthesis and chromatographic enantioresolution of anti-HIV quinolone derivatives. Talanta, 2011, 85, 1392-1397.	2.9	27
45	Studies of Antiâ€HIV Transcription Inhibitor Quinolones: Identification of Potent N1â€Vinyl Derivatives. ChemMedChem, 2010, 5, 1880-1892.	1.6	26
46	o-Chlorobenzenesulfonamidic derivatives of (aryloxy)propanolamines as .beta.-blocking/diuretic agents. Journal of Medicinal Chemistry, 1993, 36, 157-161.	2.9	25
47	A 6-Aminoquinolone Compound, WC5, with Potent and Selective Anti-Human Cytomegalovirus Activity. Antimicrobial Agents and Chemotherapy, 2009, 53, 312-315.	1.4	25
48	Functionalized 2,1-benzothiazine 2,2-dioxides as new inhibitors of Dengue NS5 RNA-dependent RNA polymerase. European Journal of Medicinal Chemistry, 2018, 143, 1667-1676.	2.6	24
49	Broad spectrum anti-flavivirus pyridobenzothiazolones leading to less infective virions. Antiviral Research, 2019, 167, 6-12.	1.9	24
50	4-(Phenoxy) and 4-(benzyloxy)benzamides as potent and selective inhibitors of mono-ADP-ribosyltransferase PARP10/ARTD10. European Journal of Medicinal Chemistry, 2018, 156, 93-102.	2.6	23
51	1,2,4-Triazolo[1,5-a]pyrimidines as a Novel Class of Inhibitors of the HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity. Molecules, 2020, 25, 1183.	1.7	23
52	Synthesis and antibacterial evaluation of [1,3]benzothiazino[3,2-a]quinoline- and [3,1]benzothiazino[1,2-a]quinoline-6-carboxylic acid derivatives. Bioorganic and Medicinal Chemistry, 1997, 5, 1339-1344.	1.4	22
53	Chemometric Methodologies in a Quantitative Structureâ^'Activity Relationship Study:Â The Antibacterial Activity of 6-Aminoquinolones. Journal of Medicinal Chemistry, 1997, 40, 1698-1706.	2.9	21
54	QSAR study and VolSurf characterization of anti-HIV quinolone library. Journal of Computer-Aided Molecular Design, 2001, 15, 203-217.	1.3	21

#	Article	IF	Citations
55	Binding studies and GRIND/ALMOND-based 3D QSAR analysis of benzothiazine type KATP-channel openers. Bioorganic and Medicinal Chemistry, 2005, 13, 5581-5591.	1.4	21
56	Synthesis and biological evaluation of 2-phenylquinolones targeted at Tat/TAR recognition. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 714-717.	1.0	21
57	Boosting Effect of 2-Phenylquinoline Efflux Inhibitors in Combination with Macrolides against Mycobacterium smegmatis and Mycobacterium avium. ACS Infectious Diseases, 2015, 1, 593-603.	1.8	21
58	Searching for innovative quinolone-like scaffolds: synthesis and biological evaluation of 2,1-benzothiazine 2,2-dioxide derivatives. MedChemComm, 2012, 3, 1092.	3.5	20
59	1,4-Benzothiazine ATP-Sensitive Potassium Channel Openers: Modifications at the C-2 and C-6 Positions. Journal of Medicinal Chemistry, 2013, 56, 4718-4728.	2.9	20
60	Potent and broad-spectrum cycloheptathiophene-3-carboxamide compounds that target the PA-PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance. Antiviral Research, 2019, 165, 55-64.	1.9	20
61	1,4â€Benzothiazineâ€2â€carboxylic acid 1â€oxides as analogues of antibacterial quinolones. Journal of Heterocyclic Chemistry, 1992, 29, 375-382.	1.4	19
62	Studies on 6-Aminoquinolones: synthesis and antibacterial evaluation of 6-amino-8-ethyl- and 6-amino-8-methoxyquinolones. Bioorganic and Medicinal Chemistry, 1999, 7, 2465-2471.	1.4	19
63	From Cromakalim to Different Structural Classes of KATP Channel Openers. Current Topics in Medicinal Chemistry, 2006, 6, 1049-1068.	1.0	19
64	Novel In Vivo Model for the Study of Human Immunodeficiency Virus Type 1 Transcription Inhibitors: Evaluation of New 6-Desfluoroquinolone Derivatives. Antimicrobial Agents and Chemotherapy, 2007, 51, 1407-1413.	1.4	19
65	Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands. Bioorganic and Medicinal Chemistry, 2014, 22, 4658-4666.	1.4	19
66	Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position. European Journal of Medicinal Chemistry, 2018, 155, 428-433.	2.6	19
67	Quinolinecarboxylic acids. 3. Synthesis and antibacterial evaluation of 2-substituted 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids related to rufloxacin. Journal of Medicinal Chemistry, 1993, 36, 3449-3454.	2.9	18
68	Chemometric rationalization of the structural and physicochemical basis for selective cyclooxygenase-2 inhibition: toward more specific ligands. Journal of Computer-Aided Molecular Design, 2000, 14, 277-291.	1.3	18
69	A Novel and Efficient Approach to Discriminate between Pre- and Post-Transcription HIV Inhibitors. Molecular Pharmacology, 2005, 67, 1574-1580.	1.0	18
70	2â€Phenylquinolones as Inhibitors of the HIVâ€1 Tatâ€“TAR Interaction. ChemMedChem, 2009, 4, 935-938.	1.6	18
71	Design, Synthesis, and Evaluation of WC5 Analogues as Inhibitors of Human Cytomegalovirus Immediateâ€Earlyâ€…2 Protein, a Promising Target for Antiâ€HCMV Treatment. ChemMedChem, 2013, 8, 1403-1414.	1.6	18
72	Inhibition of Influenza Virus Polymerase by Interfering with Its Proteinâ€“Protein Interactions. ACS Infectious Diseases, 2021, 7, 1332-1350.	1.8	18

#	Article	IF	Citations
73	Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules. Journal of Medicinal Chemistry, 2022, 65, 7532-7560.	2.9	18
74	Antiviral 6-amino-quinolones: Molecular basis for potency and selectivity. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4247-4251.	1.0	17
75	Discovery of potent p38Î± MAPK inhibitors through a funnel like workflow combining in silico screening and inÂvitro validation. European Journal of Medicinal Chemistry, 2019, 182, 111624.	2.6	17
76	Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase. European Journal of Medicinal Chemistry, 2021, 209, 112944.	2.6	17
77	From Small to Powerful: The Fragments Universe and its “Chem-Appeal”. Current Medicinal Chemistry, 2013, 20, 1355-1381.	1.2	17
78	Velnacrine thiaanalogues as potential agents for treating alzheimer's disease. Bioorganic and Medicinal Chemistry, 2001, 9, 2921-2928.	1.4	16
79	Accounting for Target Flexibility and Water Molecules by Docking to Ensembles of Target Structures: The HCV NS5B Palm Site I Inhibitors Case Study. Journal of Chemical Information and Modeling, 2014, 54, 481-497.	2.5	16
80	2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors. Scientific Reports, 2018, 8, 1680.	1.6	16
81	From cycloheptathiophene-3-carboxamide to oxazinone-based derivatives as allosteric HIV-1 ribonuclease H inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 55-74.	2.5	16
82	4Hâ€1â€benzothiopyranâ€4â€oneâ€3â€carboxylic acids and 3,4â€dihydroâ€2Hâ€isothiazolo[5,4â€bbenzothiopyranâ€3,4â€diones as quinolone antibacterial analogs. Journal of Heterocyclic Chemistry, 1993, 30, 1143-1148.	1.4	15
83	The 6-Aminoquinolone WC5 Inhibits Different Functions of the Immediate-Early 2 (IE2) Protein of Human Cytomegalovirus That Are Essential for Viral Replication. Antimicrobial Agents and Chemotherapy, 2014, 58, 6615-6626.	1.4	15
84	Molecular View of Ligands Specificity for CAG Repeats in Anti-Huntington Therapy. Journal of Chemical Theory and Computation, 2015, 11, 4911-4922.	2.3	15
85	Studies on Cycloheptathiopheneâ€3â€carboxamide Derivatives as Allosteric HIVâ€1 Ribonucleaseâ€…H Inhibitors. ChemMedChem, 2016, 11, 1709-1720.	1.6	15
86	1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors. European Journal of Medicinal Chemistry, 2021, 221, 113494.	2.6	15
87	The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogenâ€Activated Protein Kinase Inhibitors. Chemical Biology and Drug Design, 2015, 86, 531-545.	1.5	14
88	6â€Hydrogenâ€8â€Methylquinolones Active Against Replicating and Nonâ€replicating Mycobacterium tuberculosis. Chemical Biology and Drug Design, 2012, 80, 781-786.	1.5	13
89	C-2 phenyl replacements to obtain potent quinoline-based Staphylococcus aureus NorA inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 584-597.	2.5	13
90	Recent advances in the identification of Tat-mediated transactivation inhibitors: progressing toward a functional cure of HIV. Future Medicinal Chemistry, 2016, 8, 421-442.	1.1	12

#	Article	IF	Citations
91	Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors. European Journal of Medicinal Chemistry, 2020, 201, 112420.	2.6	12
92	Modifications on C6 and C7 Positions of 3-Phenylquinolone Efflux Pump Inhibitors Led to Potent and Safe Antimycobacterial Treatment Adjuvants. ACS Infectious Diseases, 2019, 5, 982-1000.	1.8	10
93	Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. ACS Medicinal Chemistry Letters, 2022, 13, 855-864.	1.3	10
94	Ethyl 1,8-Naphthyridone-3-carboxylates Downregulate Human Papillomavirus-16 E6 and E7 Oncogene Expression. Journal of Medicinal Chemistry, 2014, 57, 5649-5663.	2.9	9
95	From Quinoline to Quinazolineâ€Based S. aureus NorA Efflux Pump Inhibitors by Coupling a Focused Scaffold Hopping Approach and a Pharmacophore Search. ChemMedChem, 2021, 16, 3044-3059.	1.6	9
96	Dibenzo[1,6]naphthyridindiones as modified quinolone antibacterials. European Journal of Medicinal Chemistry, 1998, 33, 899-903.	2.6	8
97	Structural Modifications of the Quinolin-4-yloxy Core to Obtain New Staphylococcus aureus NorA Inhibitors. International Journal of Molecular Sciences, 2020, 21, 7037.	1.8	8
98	8â€Methylâ€7â€substitutedâ€1,6â€naphthyridineâ€3â€carboxylic acids as New 6â€desfluoroquinolone antibacterials. Journal of Heterocyclic Chemistry, 1999, 36, 953-957.	1.4	6
99	Sustainable, three-component, one-pot procedure to obtain active anti-flavivirus agents. European Journal of Medicinal Chemistry, 2021, 210, 112992.	2.6	6
100	Potent 2,3-dihydrophthalazine-1,4-dione derivatives as dual inhibitors for mono-ADP-ribosyltransferases PARP10 and PARP15. European Journal of Medicinal Chemistry, 2022, 237, 114362.	2.6	5
101	Modulation of HIV-1-Induced Activation of Plasmacytoid Dendritic Cells by 6-Desfluoroquinolones. AIDS Research and Human Retroviruses, 2014, 30, 345-354.	0.5	3
102	Triazolopyrimidine Nuclei: Privileged Scaffolds for Developing Antiviral Agents with a Proper Pharmacokinetic Profile. Current Medicinal Chemistry, 2022, 29, 1379-1407.	1.2	3
103	6-Hydroxy Derivative as New Desfluoroquinolone (DFQ): Synthesis and DNA-Binding Study. Nucleosides, Nucleotides and Nucleic Acids, 2000, 19, 1327-1336.	0.4	2
104	Synthesis of 2-(Arylamino)ethanethiols via Lewis Acid Catalyzed Aminolysis of 2,2-Dimethylthiirane as Precursors of the 1,4-Benzothiazine Nucleus. Synthesis, 2009, 2009, 1513-1519.	1.2	2
105	Design and Synthesis of WM5 Analogues as HIV-1 TAR RNA Binders. Open Medicinal Chemistry Journal, 2019, 13, 16-28.	0.9	2
106	7-(Disubstituted thiazolyl)-3,5-dihydroxy-6-heptenoic/heptanoic acid derivatives as HMG-COa reductase inhibitors. Bioorganic and Medicinal Chemistry, 1994, 2, 799-806.	1.4	0
107	Inhibition of cell growth and induction of apoptosis in human prostate cancer cell lines by 6-aminoquinolone WM13. Oncology Reports, 2005, 13, 1113.	1.2	0
108	Inside Cover: Studies of Anti-HIV Transcription Inhibitor Quinolones: Identification of Potent N1-Vinyl Derivatives (ChemMedChem 11/2010). ChemMedChem, 2010, 5, 1798-1798.	1.6	0